91-105 of 813
Valbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO Study
Psychiatry and Mental HealthValbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO Study
Christoph U. Correll, MD
Valbenazine for TD: Consistent Long-Term Efficacy Across Racial and Ethnic Subgroups in KINECT-4
Psychiatry and Mental HealthValbenazine for TD: Consistent Long-Term Efficacy Across Racial and Ethnic Subgroups in KINECT-4
Jonathan M. Meyer, MD
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiersDecoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Ryan Quigley
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiersTiming Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Modern MS Management: Leveraging Technology to Support Brain Health
On the Frontlines of Multiple SclerosisModern MS Management: Leveraging Technology to Support Brain Health
Victoria Leavitt, PhD
Gates B. Colbert, MD
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiersClemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
- advertisement
Targeting CD19 in Autoimmune Neuropathy: Case Report Insights
Living RheumTargeting CD19 in Autoimmune Neuropathy: Case Report Insights
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiersAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Marc Haut, PhD
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
NeuroFrontiersTransforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
Marc Haut, PhD
Addressing Barriers to MenB and MenACWY Vaccination
VacciNationAddressing Barriers to MenB and MenACWY Vaccination
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
VacciNationEvaluating MenB Vaccines Beyond the Traditional hSBA Assay
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiersThe Future of MS Management: Novel Agents and Clinical Approaches
Marisa McGinley, DO
- advertisement
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiersMS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
NeuroFrontiersPregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiersReevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
